Skip to main content

Table 2 Nordic treatment regimen for MCL

From: Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

  MCL1: 1996–2000 [16] MCL2: 2000–2006 [8, 9] MCL3: 2005–2009 [29]
No. 41 160 160
Median age (range), y 56 (38–65) 56 (32–65) 58 (28–65)
MIPI score (%)
Low/Int/High
8/46/23/23a 51/26/23 48/31/21
Induction Maxi-CHOP21a R-Maxi-CHOP21 alternating with R-HD-Ara-c R-Maxi-CHOP21 alternating with R-HD-Ara-c
Intensification therapy BEAM/BEAC+ASCT BEAM/BEAC+ASCT+/− rituximab BEAM/BEAC+ (Zevalin, if<CR) + ASCT
ORR(%) 96 96 97
CR (%) 89 54 82
Follow-up (ys) 2.8 11.4 4.4
mPFS (ys) 4-y FFS, 20% 8.5 NR (4-y PFS, 71%)
mOS (ys) 4-y OS, 61% 12.7 NR (4-y OS, 78%)
TRM (%) 2 7 6
Second malignancy(%) 7 6 4
  1. Abbreviations as indicated in the Table 1
  2. Note: FFS failure-free survival, a IPI Low/Low-Inter/Inter-High/High; BEAM/BEAC Carmustine, etoposide, cytarabine, and melphalan or the same regimen with cyclophosphamide instead of melphalan; Zevalin, 90Y-ibritumomab-tiuxetan